При 48- седмичен анализ в рамките на проучването ARTEMIS (вж.
In the 48 week analysis of the ARTEMIS trial (see Clinical experience subsection ART-naïve patients), 9.9% virologic failures were observed in patients receiving PREZISTA/ritonavir 800/100 mg q.d.